Recombinant Human Growth Hormone Plus Recombinant Human Insulin-Like Growth Factor-1 Coadministration Therapy in Short Children with Low Insulin-Like Growth Factor-1 and Growth Hormone Sufficiency: Results from a Randomized, Multicenter, Open-Label, Parallel-Group, Active Treatment-Controlled Trial
Author(s) -
Philippe Backeljauw,
Bradley S. Miller,
Pascale Dutailly,
Aude Houchard,
Elizabeth A. Lawson,
Daniel E. Hale,
Barry Reiner,
Mark A. Sperling
Publication year - 2015
Publication title -
hormone research in paediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.816
H-Index - 89
eISSN - 1663-2826
pISSN - 1663-2818
DOI - 10.1159/000371799
Subject(s) - medicine , endocrinology , insulin like growth factor , idiopathic short stature , randomized controlled trial , insulin , short stature , growth factor , adverse effect , population , growth hormone treatment , recombinant dna , growth hormone , hormone , biology , receptor , biochemistry , gene , environmental health
Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) both contribute to growth. To determine if recombinant human (rh)GH + rhIGF-1 therapy is more effective than rhGH alone to treat short stature, we assessed the efficacy and safety of coadministered rhGH + rhIGF-1 in short children with GH sufficiency and low IGF-1.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom